Recorna's Wholly-Owned Subsidiary, Sequenova (Hong Kong) Biotech, Officially Opens in Hong Kong Science Park and Files IPO Prospectus

Jan 20, 2025 08:16 CST Updated 08:16

RecoRNA

Innovative Drug Developer

Recently, Xuxin (Hong Kong) Biotechnology Co., Ltd. (hereinafter referred to as "Hong Kong Xuxin Bio"), officially moved into Hong Kong Science Park and successfully opened!

Opening Ceremony of RecoRNA (Hong Kong)

Hong Kong Xuxin Biotechnology is a wholly-owned subsidiary established in Hong Kong in 2024 by RECORNA (Guangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "RecoRNA"). RecoRNA was founded by a team of scientists led by a returnee doctor from Stanford University and pharmaceutical executives with operational management experience in international and Chinese pharmaceutical companies. It is a research and development company that develops innovative drugs based on targeted RNA editing technology. As the R&D center set up by RecoRNA in Hong Kong, Hong Kong Xuxin Biotechnology is committed to the development of AI platform technology. Driven by the AI platform, it can screen out better drug molecules more quickly, thereby accelerating the R&D process of the company's innovative drugs.

About RecoRNA

RecoRNA is a drug research and development company that focuses on developing innovative drugs for indications without effective conventional treatments through its RNA editing technology platform. The key therapeutic areas include cardiovascular and cerebrovascular diseases, neurological disorders, respiratory conditions, anti-aging, and other fields with significant unmet clinical needs. The company’s leading pipeline, aimed at treating neurological diseases, has completed preliminary molecular research and is currently in the preclinical stage, with an expected IND filing in 2025. RecoRNA, based on the technology transfer from Professor Rui Zhang's lab at Sun Yat-sen University's School of Life Sciences, has established its proprietary RNA editing platform. Located in the Bio Island Innovation Center in Guangzhou, RECORNA (Guangzhou) Biotechnology Co., Ltd. has built a comprehensive R&D platform encompassing drug discovery, biological validation, and delivery system development.

E.N.D

Previous article recommendations:

Net income exceeds $1 billion, the first AAV gene therapy product for DMD shows strong market performance

China's Leading Culture Medium Company Acquires a CRO Company

Zhejiang Releases New Policy, Emphasizing the Development of Innovative Drugs and Therapies Such as Cell Immunotherapy, Gene Therapy, and Antibody-Drug Conjugates

$810 Million! Two AAV Gene Therapy Out-Licensing Collaborations Achieved

Over 700 Million Yuan! In Vivo CAR-T Therapy Start-Up Exceeds C-Round Financing Target

Chinese Scientists Achieve Significant Breakthrough, Induce Human iPS Cells in as Fast as 10 Days

China's National Medical Products Administration Inspection Center Releases "Guidelines for the Production Inspection of Cell Therapy Products"

World's First! RecoRNA's Umbilical Cord Blood-Derived Universal CAR-T Product Approved for Clinical Trials in the U.S.

People's Daily: China's stem cell market is expected to exceed 25 billion yuan, with over 30 companies布局stem cell drugs

A Cell and Gene Therapy Company in China Completes a New Round of Financing Worth Hundreds of Millions

China's First Stem Cell Therapy Approved for Marketing

First Case in the Province! Zhejiang University Second Hospital Applies CAR-NK Cell Therapy to Treat Three Systemic Lupus Erythematosus Patients

CDE Releases "Nonclinical Research Technical Guidelines for Adeno-Associated Virus Vector Gene Therapy Products," Effective Immediately Upon Release

CDE Releases "Technical Guiding Principles for Clinical Trials of Chimeric Antigen Receptor T-Cell Therapy in Hematological and Lymphatic System Malignancies (Trial)"

Novartis SMA Gene Therapy Phase III Clinical Trial Successful for Ages 2-18

Advances in the Development of iPSC-Derived NK Cell Therapy

Five Departments Jointly Issued the "Three-Year Action Plan for the Innovative Development of Beijing's Cell and Gene Therapy Industry" (Policy Interpretation Attached at the End)

6 Hours to Complete CAR-T Preparation, Shanghai Cell Therapy Group’s Triple-Target CAR-T Treatment Achieves Rapid Complete Remission in First Patient

Science Releases Top 10 Scientific Breakthroughs of 2024

Nature|First "Clear View" of Core Protein in Muscular Dystrophy! Provides New Clues for Gene Therapy in Muscular Dystrophy

7-Day Completion of Autologous CAR-T Cell Manufacturing and Infusion, New Therapy with Ultra-High Remission Rate Reveals Latest Research Results

China's First Nucleic Acid Drug CDMO Base Officially Begins Operations

First in China! Clinical Approval Granted for New Diabetes Treatment Using Pluripotent Stem Cell-Derived Islet Cells

Disclaimer: The content is sourced fromOfficial company channels, etc.This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.